Open up horizons and overview the prospects of ASCT - CSCO Autologous Transplantation Working Group 2022 Tour - Myeloma and Leukemia Special Session (Beijing Station) was a complete success

After the opening ceremony, the academic session followed and unfolded
in full swing.
The first part of the academic report was chaired by Professor Zhou Daobin of Peking Union Medical College Hospital.

Professor Zhou Daobin served as the chair of the first part of the academic report

Professor Liu Weiping of Peking University Cancer Hospital gave a detailed description of the national ASCT and lymphoma and multiple myeloma (MM) ASCT in 2021 in the report "Current Status and Prospect of Autologous Hematopoietic Stem Cell Transplantation in China".

The degree of ASCT development in China is still insufficient, and high-level evidence-based medical evidence is lacking
.
In 2021, a total of 5221 ASCT cases were reported from 211 centers in 29 provinces and cities in China, and a total of 4556 cases of first ASCT for lymphoma and myeloma, including 2443 lymphoma patients (ASCT utilization rate of 2.
4%) and 2113 myeloma patients (ASCT utilization rate of 11.
3%)
。 A series of multicenter retrospective and prospective studies conducted in China have found that ASCT brings good survival benefits to patients with mantle cell lymphoma, peripheral T-cell lymphoma and T-lymphoblastic lymphoma.
In addition, the combination of ASCT and new drugs and therapies is also a future development trend, which can bring clinical benefits
to patients.
In the future, the development of ASCT in China depends on the training of professional personnel and teams, and it is expected to carry out more high-quality clinical studies
suitable for Chinese patients in the future.

Professor Liu Weiping made a report

The discussion session was moderated by Professor Liu Kaiyan from the Institute of Hematology, Peking University, and the guests were Professor Jing Hongmei of Peking University Third Hospital and Professor Dong Yujun of Peking University First Hospital on "The Future Development Space of ASCT", "The Establishment of ASCT Database", " Professor Liu Weiping had an in-depth discussion on the acceptance of ASCT by patients" and "the change of concepts of ASCT between doctors and patients", and the academic atmosphere was strong
.

Professor Liu Kaiyan chaired the discussion part of the first session

The second part of the academic report was chaired by Professor Chen Wenming of Beijing Chaoyang Hospital affiliated to Capital Medical University.

Professor Chen Wenming served as the chair of the second part of the academic report

Professor Lu Jin of Peking University People's Hospital gave a detailed interpretation of the China MM ASCT Guidelines 2021 Edition, which includes transplant status and patient screening; induction therapy and timing of transplantation; stem cell mobilization, collection and preservation; pretreatment and stem cell infusion; post-transplant hematopoietic and immune reconstitution monitoring; Consolidation and maintenance therapy after ASCT, as well as double transplantation and salvage secondary transplantation
.
Professor Lu Jin mentioned that the average age of diagnosis of MM patients in China is about 10 years younger than that of European and American countries, but the proportion of patients receiving ASCT is significantly lower than that in European and American countries, which may be one of
the reasons why the progression-free survival (PFS) and overall survival (OS) of Chinese MM patients are significantly worse than those in Europe and the United States 。 In order to increase the number of patients treated for ASCT, it may be possible to learn from the Mayo Clinic experience, except for patients whose upper respiratory tract mucosa requires antibiotic therapy, supraventricular tachycardia, physical weakness and inability to visit the outpatient clinic daily for infusions, and/or are completely unaccompanied by family members
.

Professor Lu Jin gave a report

In the subsequent discussion session, under the chairmanship of Professor Song Yuqin of Peking University Cancer Hospital, Professor Li Zhenling of China-Japan Friendship Hospital and Professor Liu Hui of Beijing Hospital participated in the discussion, and had wonderful exchanges on topics such as "Selection of Double ASCT Patients" and "Programming and Standardization of Stem Cell Preservation"
。

Professor Song Yuqin served as the chair of the discussion part of the second session

The third part of the academic report was chaired by Professor Jiang Bin of
Peking University People's Hospital.

Professor Jiang Bin served as the chair of the third part of the academic report

Professor Wang Yu from Peking University People's Hospital gave a detailed report on the consensus and guideline recommendations of ASCT and the results of clinical research on the topic of "Autologous peripheral blood hematopoietic stem cell transplantation in the treatment of low-risk intermediate-critical acute leukemia".

Professor Wang Yu mentioned that ASCT has good safety in the treatment of acute myeloid leukemia (AML), and the efficacy of low-risk and intermediate-risk AML is acceptable, which can be used as an option
for consolidation therapy for low- and intermediate-risk AML patients, especially those with minimal residual disease (MRD)-negative.
In addition, intensified pretreatment may reduce the likelihood of AML recurrence; When relapse after ASCT, related human leukocyte antigen (HLA) incompatibility transplantation can be used as one of
the treatment options for AML patients.
In patients with PH-positive acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplantation (allo-HSCT) and ASCT each predominate in disease recurrence and transplant-related death (TRM), with no significant difference
in recurrence-free survival.

Professor Wang Yu gave a report

The discussion session was moderated by Professor Liu Daihong of the Chinese General Hospital of the People's Liberation Army, Professor Gong Tiejun of Harbin Hematology Cancer Hospital and Professor Cao Xingyu of Beijing Lu Daopei Hospital The participants actively discussed
the issues of "MRD negative conversion criteria", "application of transplantation in patients with AML1-ETO and CBFβ-MYH11-positive acute myeloid leukemia", and "selection of pretreatment protocol for ASCT in leukemia patients".

Professor Liu Daihong chaired the discussion part of the third session

The fourth session of the academic report was chaired by Professor Zhuang Junling of Peking Union Medical College Hospital.

Professor Zhuang Junling served as the chair of the fourth part of the academic report

Professor Gao Wen of Beijing Chaoyang Hospital affiliated to Capital Medical University first briefly introduced the definition of MM kidney damage, the clinical phenotype and pathological phenotype
of MM kidney damage in the report "ASCT Treatment with Renal Damage".
MM renal lesions are nephropathy caused by MM with pathologically confirmed monoclonal globulin deposition, and the most characteristic MM renal lesions are cast-type nephropathy
.
Subsequently, Professor Gao Wen introduced in detail the selection and benefits
of ASCT treatment of MM with renal damage.
In the pretreatment stage, the application of new drugs improved the prognosis of patients with MM with renal impairment, and the three-drug combination regimen was better than the two-drug regimen, for example, the VPD (bortezomib + pomalidomide + dexamethasone) regimen was better than the VD (bortezomib + dexamethasone) regimen
.
From the current data, MM stem cell mobilization with renal damage is similar to that without renal loss, and steady-state mobilization
is recommended.
ASCT can improve renal remission rate and survival in patients with MM with renal impairment, but it needs to be explored in the future to further optimize induction therapy and transplantation therapy
with MM with renal damage.

Professor Gao Wen gave a report

Professor Cen Xinan from Peking University First Hospital and Professor Wang Liang from Beijing Tongren Hospital affiliated to Capital Medical University discussed "Proportion and benefits of ASCT in patients with moderate renal impairment" and Which type of renal damage pathology patients benefit more after ASCT", and other issues, and the participants had a lively discussion
.

Professor Wang Fengrong chaired the discussion part of the fourth session